Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Erythromycin (Erythrocin®, Erythromycin®, Erythroped®) is a macrolide antimicrobial occasionally used in dogs and cats for selected susceptible bacterial infections. It is not commonly used in small animal practice today because newer macrolides are often better tolerated and more convenient to dose.
In addition to its antibacterial effects, erythromycin can stimulate gastrointestinal motilin receptors, giving it prokinetic properties that may be useful in certain disorders involving delayed gastric emptying or reduced upper gastrointestinal motility.
Mechanism of Action (MOA): Erythromycin binds to the 50S bacterial ribosomal subunit and inhibits protein synthesis by interfering with peptide bond formation. This produces time-dependent antibacterial activity against susceptible organisms.
Erythromycin has activity mainly against many Gram-positive organisms and selected atypical or fastidious bacteria, while many Enterobacteriaceae are resistant. Different salt or ester formulations may vary in absorption and tolerability.
Indications
Erythromycin is used infrequently in dogs and cats, but may be considered when culture results, organism susceptibility, or clinical circumstances support its use. It may also be used at lower doses for gastrointestinal prokinetic effects.
- Susceptible Gram-positive bacterial infections: May be used for selected infections caused by susceptible staphylococci, streptococci, and other Gram-positive organisms.
- Pasteurella infections: May have activity against some susceptible Pasteurella isolates.
- Atypical or intracellular pathogens: May be considered in selected infections involving susceptible Chlamydophila, Rickettsia, Actinomyces, or Nocardia species.
- Canine enteric Campylobacter: May be considered in selected canine gastrointestinal infections when clinically indicated.
- Alternative macrolide therapy: May be selected when other macrolides are unavailable or unsuitable and susceptibility is expected.
- Gastrointestinal prokinetic use: Low-dose erythromycin may be used to stimulate motility in cases of delayed gastric emptying or upper GI hypomotility.
Dosage (Reference)
Dog
Erythromycin may be used in dogs either as an antimicrobial at standard therapeutic doses or at lower doses for gastrointestinal prokinetic support. Dose interval depends on the intended use.
| Clinical use | Route | Dose | Notes |
|---|---|---|---|
| Antibacterial therapy | PO | 10–20 mg/kg every 8–12 hours | Use when susceptible infection is suspected or confirmed. |
| GI prokinetic effect | PO | 0.5–1 mg/kg every 8 hours | Lower doses used to stimulate motility rather than provide antibacterial action. |
• Oral administration is recommended in the supplied reference.
• As erythromycin base is acid-labile, giving on an empty stomach may improve absorption when tolerated.
• Gastrointestinal upset may limit dosing tolerance in some dogs.
• Follow responsible antimicrobial use principles whenever used as an antibiotic.
Cat
In cats, erythromycin may be used orally for selected susceptible infections or at lower doses for prokinetic purposes. Palatability and gastrointestinal tolerance should be considered.
| Clinical use | Route | Dose | Notes |
|---|---|---|---|
| Antibacterial therapy | PO | 10–20 mg/kg every 8–12 hours | Use based on likely susceptibility or culture results. |
| GI prokinetic effect | PO | 0.5–1 mg/kg every 8 hours | Used at low doses to promote upper GI motility. |
• Oral dosing only was listed in the supplied source.
• Administer on an empty stomach when tolerated to optimize absorption.
• Monitor for vomiting, reduced appetite, or poor acceptance.
• Use antimicrobial stewardship principles for infectious indications.
Warnings & Precautions
Erythromycin should be used cautiously in dogs and cats because gastrointestinal intolerance is common, and clinically relevant drug interactions may occur. Patient history, concurrent medications, and hepatic status should be reviewed before treatment.
- Gastrointestinal intolerance: Vomiting, nausea, abdominal discomfort, and diarrhea are common and may limit use.
- Hepatic dysfunction: Use cautiously in patients with liver disease. Certain formulations have been associated with cholestatic hepatitis in humans.
- Renal impairment: Use carefully in patients with reduced renal function, particularly if dehydration or concurrent illness is present.
- Formulation differences: Different salts or esters may vary in absorption, tolerability, and adverse effect profile.
- Administration timing: Because erythromycin base is acid-labile, administration on an empty stomach may improve absorption when tolerated.
- Resistance concerns: Bacterial resistance can be significant, especially among staphylococcal organisms. Culture and susceptibility testing are valuable when possible.
- Do not combine similar antimicrobials: Concurrent use with other macrolides, lincosamides, or chloramphenicol may reduce efficacy because of antagonistic ribosomal competition.
- Prokinetic use caution: When used for motility support, reassess patients with vomiting, obstruction risk, or severe GI disease before treatment.
- Long-term therapy: Extended use may increase risk of adverse GI effects or selection for resistant bacteria.
- Pregnancy / lactation: Use only when benefits outweigh risks, as specific veterinary safety data may be limited.
Drug Interactions
Erythromycin has several clinically important drug interactions, mainly due to altered absorption, increased serum drug concentrations, or pharmacodynamic antagonism with other antimicrobials. A full medication review is recommended before use.
- Digoxin: Erythromycin may enhance gastrointestinal absorption and increase serum digoxin concentrations.
- Cyclosporine: May increase cyclosporine blood levels and toxicity risk.
- Cisapride: May significantly increase arrhythmia risk; this combination is considered high risk.
- Theophylline: Serum theophylline concentrations may increase, raising toxicity risk.
- Methylprednisolone: May increase corticosteroid exposure and adverse effect potential.
- Terfenadine: Serious cardiac arrhythmias were reported in human medicine; avoid concurrent use where relevant.
- Other macrolides: Concurrent use is discouraged because antagonism or overlapping toxicity may occur.
- Lincosamides (e.g., clindamycin): May antagonize antibacterial activity due to competition at similar ribosomal binding sites.
- Chloramphenicol: May reduce efficacy of one or both drugs because of overlapping 50S ribosomal binding.
Side Effects & Overdose
Side Effects
Adverse effects of erythromycin in dogs and cats are most commonly gastrointestinal. Severity may depend on dose, formulation used, and individual patient tolerance.
- Vomiting: One of the most frequently reported adverse effects.
- Diarrhea: Loose stool or increased fecal frequency may occur.
- Nausea / abdominal discomfort: May present as drooling, food aversion, restlessness, or abdominal sensitivity.
- Reduced appetite: Inappetence may occur secondary to GI irritation.
- Flatulence or cramping: Increased GI motility may cause abdominal discomfort in some patients.
- Hepatic effects: Elevated liver enzymes or cholestatic reactions are possible, especially in susceptible patients.
- Altered intestinal flora: Extended use may contribute to dysbiosis or secondary GI upset.
- Hypersensitivity reactions: Rare allergic reactions such as rash, facial swelling, or pruritus may occur.
Overdose
Erythromycin overdose is expected to primarily exaggerate gastrointestinal and hepatic adverse effects. Most cases are managed supportively.
- Severe vomiting and diarrhea: Most common overdose signs and may lead to dehydration.
- Marked abdominal discomfort: Cramping, restlessness, or hypersalivation may occur.
- Anorexia: Temporary refusal to eat may follow overdose exposure.
- Dehydration: Secondary to fluid losses from persistent GI signs.
- Lethargy: May develop with dehydration or systemic upset.
- Liver stress: Significant overdose may increase risk of hepatic injury, especially in predisposed patients.
- Management: No specific antidote exists. Provide supportive care, control vomiting, maintain hydration, and monitor clinical status.
- Hospitalization: Recommended for persistent vomiting, inability to maintain hydration, severe lethargy, or patients with preexisting liver disease.
Key Notes
Practical clinical points that may help optimize the safe and effective use of erythromycin in dogs and cats:
- Older macrolide role: Erythromycin is less commonly selected today because newer macrolides often offer easier dosing and better tolerance.
- Two-purpose drug: The same medication may be used differently depending on dose goal—antibacterial therapy versus motility support.
- Culture helps decisions: Because resistance patterns can be unpredictable, laboratory guidance is especially valuable when treating infections.
- Short courses preferred when possible: Limiting unnecessary duration may reduce GI intolerance and antimicrobial resistance pressure.
- Assess stool quality during therapy: Changes in feces can be an early indicator that treatment tolerance is declining.
- Useful when feeding tubes are present: Oral liquid formulations may be practical in selected hospitalized patients needing enteral administration.
- Prokinetic response varies: Some patients show meaningful motility improvement, while others have minimal clinical benefit.
- Palatability matters in cats: Acceptance can strongly influence treatment success, so administration technique may need adjustment.
- Reassess if no improvement: Lack of clinical response should prompt reconsideration of diagnosis, drug choice, or underlying disease process.
Calculate Any Dose Instantly
Use our smart dose calculator to get accurate dosing for 500+ veterinary drugs — adjusted for species, weight, and route.
